Search
Regenxbio Inc
RGNXAdd to Watchlist
8.530USD
-0.030-0.35%
Close 09-11 16:00（ET）
460.94MMarket Cap
LossP/E TTM
Regenxbio Inc (RGNX) Stock Price Target & Forecast
Analyst Rating
Based on 13 analysts giving stock ratings to Regenxbio Inc in the past month.
Buy
4 Strong Buy
8 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
24.417USD+186.24%
RGNX Analyst Recommendation Trends
In the current month, RGNX has received 8 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. RGNX average Analyst price target in the last month is 24.417.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
4
4
4
4
4
4
4
4
8
8
8
8
8
8
8
8
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13
13
13
13
13
13
13
13
RGNX Analyst Rating for Peer Comparison
Updated: Sep 13, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
8
13
2
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Ascendis Pharma A/S
ASND
10
10
0
0
0
20
Financial Forecasting
Based on analysts' estimates, RGNX EPS is projected to reach -1.208 in FY2026Q3, following reported EPS of 0.430 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.96
-1.34
0.06
-1.21
-0.91
Actual
-1.30
-1.72
0.43
--
--
Surprise
-35.71%
-28.29%
+641.26%
--
--
FAQs
What is Regenxbio Inc's expected revenue for the next quarter?
Regenxbio Inc's expected revenue is 15.86M.
What is Regenxbio Inc's price target?
Analysts forecast that Regenxbio Inc's price target is USD 24.42, with the highest forecast at USD 50.00 and the lowest forecast at USD 10.00.
How have Regenxbio IncRGNX's recent earnings per share performed?
The market expectation was USD 0.43, while Regenxbio IncRGNX's earnings per share (EPS) for the previous quarter was USD -1.72. EPS for the next quarter is expected at USD -1.21.
What is the analyst rating for Regenxbio Inc?
Based on the ratings of Regenxbio Inc's stock from 13 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.